Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
4
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Mobocertinib
Research Leaders
5 sponsors active, led by Suzhou Puhe Pharmaceutical Technology Co., LTD
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
75%
3 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Research Network
Common Treatments
- Mobocertinib1
- Pembrolizumab1
- Ph0091 Tablet1
- Cisplatin Or Carboplatin Pemetrexed1
- Carboplatin Plus Paclitaxel1
Active Sponsors
- Suzhou Puhe Pharmaceutical Technology Co., LTD2
- Immutep S.A.S.1
- Immutep1
- Merck Sharp & Dohme LLC1
- Takeda1
Top Investigators
Puhe Biopharma